The 2025 selloff has punished plenty of ASX 200 shares, but some of the hardest-hit companies also happen to be among the highest quality on the market.
Short-term uncertainty, interest rate jitters, and tech volatility have dragged down a number of blue chip and top-tier growth names, even though their long-term outlooks remain as strong as ever.
For patient investors, this could have created a compelling opportunity to buy some of the best ASX shares out there at multi-year discounts.
Image source: Getty Images
CSL Ltd (ASX: CSL)
CSL is one of the highest-quality businesses ever to list on the ASX, yet its shares have sunk to some of their lowest valuation levels in over a decade.
This has been driven by concerns around US tariff risks, a slower-than-expected margin recovery at CSL Behring, and uncertainty surrounding the planned Seqirus demerger.
But the fundamental story has not changed. Plasma collection volumes continue to rise, CSL's therapy pipeline remains deep, and the company is investing heavily in US manufacturing to mitigate any tariff impacts over the long term.
It is also worth noting that major brokers still have price targets far above current levels, with many believing the market has overreacted. One of those is UBS, which has a buy rating and $275.00 price target on its shares.
TechnologyOne Ltd (ASX: TNE)
TechnologyOne is one of the ASX 200's most reliable compounders, delivering more than 10 consecutive years of record profits. Yet, the enterprise software provider's shares have fallen materially from their highs, dragged down by a tech correction and recurring revenue growth that was strong but just not quite as strong as some were hoping.
Nevertheless, management remains very positive and once again reiterated its expectation for the business to double in size every five years. There are not many ASX shares out there that can boast that!
This could make now an opportune time to load up on this quality tech stock. Morgan Stanley thinks it would be a good idea. The broker recently upgraded its shares to an overweight rating with a $36.50 price target.
Xero Ltd (ASX: XRO)
Finally, Xero shares have dropped heavily from their 52-week high, despite the company delivering accelerating growth across multiple geographies.
Xero now generates NZ$2.7 billion in annualised monthly recurring revenue from 4.59 million subscribers. But if you thought that was close to peaking, think again. The company estimates that the global small-business market it serves is over 100 million businesses.
As a result, Xero's growth runway remains enormous. So, for long-term investors, Xero at a multi-year discount could be a compelling opportunity to buy a global software leader well below fair value.
Macquarie recently put an outperform rating and $230.30 price target on the ASX 200 share.
